149 related articles for article (PubMed ID: 21300921)
21. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer.
Song J; Chen C; Raben D
Oncology (Williston Park); 2004 Dec; 18(14):1757-67; discussion 1767, 1771-2, 1777. PubMed ID: 15700625
[TBL] [Abstract][Full Text] [Related]
22. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?
Ang KK
J Clin Oncol; 2004 Dec; 22(23):4657-9. PubMed ID: 15534361
[No Abstract] [Full Text] [Related]
23. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell cancer].
Vladimirova LY; Agieva AA; Engibaryan MA
Vopr Onkol; 2015; 61(4):580-2. PubMed ID: 26571826
[TBL] [Abstract][Full Text] [Related]
24. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
26. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
27. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy in locally advanced head and neck cancer: a critical reappraisal.
Jassem J; Bartelink H
Cancer Treat Rev; 1995 Sep; 21(5):447-62. PubMed ID: 8556718
[No Abstract] [Full Text] [Related]
30. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
31. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL
Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514
[TBL] [Abstract][Full Text] [Related]
32. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Merlano M; Russi EG; Numico G; Colantonio I; Garrone O; Pelissero A; Granetto C; Gasco M; Di Costanzo G; Heouaine A; Vigna Taglianti R; Cipolat M
Radiother Oncol; 2005 May; 75(2):193-6. PubMed ID: 16086909
[TBL] [Abstract][Full Text] [Related]
34. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.
Perri F; Pacelli R; Della Vittoria Scarpati G; Cella L; Giuliano M; Caponigro F; Pepe S
Head Neck; 2015 May; 37(5):763-70. PubMed ID: 24995469
[TBL] [Abstract][Full Text] [Related]
35. The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation.
Matsumoto F; Valdecanas DN; Mason KA; Milas L; Ang KK; Raju U
Anticancer Res; 2012 Aug; 32(8):3029-35. PubMed ID: 22843870
[TBL] [Abstract][Full Text] [Related]
36. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Cohen EE; Haraf DJ; List MA; Kocherginsky M; Mittal BB; Rosen F; Brockstein B; Williams R; Witt ME; Stenson KM; Kies MS; Vokes EE
J Clin Oncol; 2006 Jul; 24(21):3438-44. PubMed ID: 16849759
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Paccagnella A; Mastromauro C; D'Amanzo P; Ghi MG
Oncologist; 2010; 15 Suppl 3():8-12. PubMed ID: 21036883
[TBL] [Abstract][Full Text] [Related]
38. The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Specenier P; Vermorken JB
Curr Opin Oncol; 2007 May; 19(3):195-201. PubMed ID: 17414636
[TBL] [Abstract][Full Text] [Related]
39. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S
Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609
[TBL] [Abstract][Full Text] [Related]
40. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
